AMETEK’s third quarter was marked by strong operational execution, highlighted by double-digit growth in both sales and orders, and a notable expansion in margins. Management attributed these results to robust performances across its Electromechanical and Electronic Instruments Groups, effective integration of recent acquisitions, and sustained demand in key end markets such as Aerospace & Defense and Power. CEO David Zapico credited the company’s distributed operating structure and focus on operational excellence as central to AMETEK’s ability to quickly respond to changing market dynamics and deliver solid results.

Is now the time to buy AME? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From AMETEK’s Q3 Earnings Call

• Deane Dray (RBC Capital Markets) asked about the drivers behind strong regional performance and Paragon’s contribution. CEO David Zapico highlighted broad-based growth, especially in Europe and the U.S., with Paragon Medical leading order growth in EMG.
• Matt Summerville (D.A. Davidson) inquired about Paragon Medical’s trajectory post-destocking concerns. Zapico replied that Paragon’s margins are now in line with company averages and emphasized ongoing restructuring and new program wins.
• Christopher Snyder (Morgan Stanley) questioned the organic versus acquisition-driven revenue mix in Q4. CFO Dalip Puri clarified that acquisitions would remain a mid- to high single-digit contributor, with minimal expected FX impact.
• Nigel Coe (Wolfe Research) asked for detail on discrete versus factory automation demand. Zapico explained that AMETEK’s strength is in discrete automation for precision equipment, which is rebounding more quickly than factory automation.
• Robert Wertheimer (Melius Research) sought clarity on the EMG’s outsized growth compared to EIG. Zapico linked this to the destocking cycle ending in EMG markets, particularly in medical and automation, and noted that EIG was less affected by prior inventory buildups.

Catalysts in Upcoming Quarters

In the coming quarters, our analyst team will be closely watching (1) the pace of adoption and order growth in data center and grid electrification applications, (2) integration progress and margin improvement from recent acquisitions such as Paragon Medical and FARO, and (3) sustained momentum in Aerospace & Defense content wins. Ongoing tariff negotiations and pricing discipline will also be important markers of AMETEK’s ability to navigate external headwinds.

AMETEK currently trades at $198.06, up from $184.20 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.